Solid Tumors

35 total trials 15 recruiting

Filter these 35 trials by phase, country, sponsor and more.

Open in Search →

A Phase 1, Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123 … Pending

2024-520258-39-00 3
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors (ARC-20) Recruiting

2024-519142-70-00 3 2025-11-19
Volrustomig Priming Regimens Exploratory Phase II Platform Study Recruiting

2023-509482-20-00 4 2024-12-03
Evaluation of the omission of dexamethasone in premedication regimens during paclitaxel treatment Recruiting

2023-507481-43-00 11 2024-06-25
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) Recruiting

2024-512358-78-00 7 2015-01-20
Dose Escalation and Dose Expansion Study of BBO-10203 in Subjects with Advanced Solid Tumors Recruiting

2024-519445-29-00 1 2025-10-02
Study of ORIC-114 in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration Recruiting

2024-512264-66-00 7 2025-01-29
A Phase 1 Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAS-004, a MEK (1/2) Inhibitor, in … Recruiting

2024-510900-34-00 1 2024-11-22
NANOFER-THE-0504: A Trial to Assess the Safety and Tolerability of an Investigational Drug THE-0504 for Patients With Solid Tumors Recruiting

2023-503787-17-00 1 2024-11-13
Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants with MAGE-A4 … Recruiting

2023-508808-38-00 1 2024-05-29
A Phase 1, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan in Subjects With Advanced or … Recruiting

2022-501508-82-00 3 2023-08-23
A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engag … Recruiting

2022-503133-54-00 7 2023-08-09
68Ga-FAPI-46 PET-CT for molecular assessment of fibroblast activation and risk assessment in solid tumors (FAPI Basket) Recruiting

2024-511659-17-00 4 2023-05-01
A clinical study of the safety and effectiveness of an investigational cell therapy given with and without an investigational RNA-based vacc … Recruiting

2024-514962-38-00 1 2020-08-25
Treatment of patients with solid tumors with genetically modified patients' own T-cells, recognizing a particular tumor marker Recruiting

2024-515114-41-00 7 2020-08-10
A randomized phase II clinical trial on intratumoral AS01B/ipilimumab plus intravenous nivolumab with or without autologous CD1c(BDCA-1)+ / … Recruiting

2024-517094-24-00 9 2018-01-08
A study to test different doses of BI 1831169 alone and in combination with an anti-PD-1 antibody in people with different types of advanced … Recruitment ended

2024-512504-19-00 1 2025-05-28
Phase 2 Futibatinib in Combination with PD-1 Antibody-based Standard of Care in Solid Tumors Recruitment ended

2023-507516-12-00 4 2024-05-08
Master Protocol for Encorafenib/Binimetinib Continuation Sub-Studies (FLOTILLA Study) Recruitment ended

2023-509408-13-00 6 2022-09-20
IMA401-101 – Treatment of patients with solid tumors with IMA401 TCER®, a bispecific T-cell receptor (Phase I trial); alone or in combinatio … Recruitment ended

2023-506854-19-00 1 2022-05-19
Phase 1 / 2 Study Evaluating MCLA-129 in Advanced NSCLC Recruitment ended

2024-514461-19-00 9 2021-09-09
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Recruitment ended

2023-507418-28-00 4 2021-03-15
Avelumab Program Rollover Study Recruitment ended

2024-514274-46-00 5 2019-06-21
A Phase 1 Study of BGB-B3227 Alone and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors Ended

2024-514216-27-00 1 2025-01-17

Showing 1–24 of 35 trials